Michel Puceat

Calreticulin reveals a critical Ca(2+) checkpoint in cardiac myofibrillogenesis.

Stem cell differentiation requires a paracrine pathway in the heart.

Structural adaptation of the nuclear pore complex in stem cell-derived cardiomyocytes.

A dual role of the GTPase Rac in cardiac differentiation of stem cells.

Commitment of embryonic stem cells toward a cardiac lineage: molecular mechanisms and evidence for a promising therapeutic approach for heart failure.

Stable benefit of embryonic stem cell therapy in myocardial infarction.

[Confocal microscopy: a tool to visualise differentiation of stem cells into cardiomyocytes].

Cardiac specification of embryonic stem cells.

Initiation of embryonic cardiac pacemaker activity by inositol 1,4,5-trisphosphate-dependent calcium signaling.

Fine-tuning in Ca2+ homeostasis underlies progression of cardiomyopathy in myocytes derived from genetically modified embryonic stem cells.

Interplay between the retinoblastoma protein and LEK1 specifies stem cells toward the cardiac lineage.

Administration of allogenic stem cells dosed to secure cardiogenesis and sustained infarct repair.

Cardiac commitment of embryonic stem cells for myocardial repair.

Rb and LEK1: a "pas de deux" in cardiogenesis.

Ca2+ signalling in cardiogenesis.

Transplantation of cardiac-committed mouse embryonic stem cells to infarcted sheep myocardium: a preclinical study.

[Embryonic stem cells to study early myocardial development and potential regenerative medicine].

Role of Rac-GTPase and reactive oxygen species in cardiac differentiation of stem cells.

GFP expression in muscle cells impairs actin-myosin interactions: implications for cell therapy.

Stem cell therapy in heart failure: where do we stand and where are we heading?

Oct-3/4 dose dependently regulates specification of embryonic stem cells toward a cardiac lineage and early heart development.

Oct-3/4: not just a gatekeeper of pluripotency for embryonic stem cell, a cell fate instructor through a gene dosage effect.

TGFbeta in the differentiation of embryonic stem cells.

Cardiopoietic programming of embryonic stem cells for tumor-free heart repair.

Green fluorescent protein impairs actin-myosin interactions by binding to the actin-binding site of myosin.

Is xenotransplantation of embryonic stem cells a realistic option?

Differentiation in vivo of cardiac committed human embryonic stem cells in postmyocardial infarcted rats.

Pharmacological approaches to regenerative strategies for the treatment of cardiovascular diseases.

[FISCH-ESC, the first international symposium on human embryonic stem cell research].

Protocols for cardiac differentiation of embryonic stem cells.

Cardiac commitment of primate embryonic stem cells.

Can mesenchymal stem cells induce tolerance to cotransplanted human embryonic stem cells?

The biological and ethical basis of the use of human embryonic stem cells for in vitro test systems or cell therapy.

An in vitro beating heart model for long-term assessment of experimental therapeutics.

Human embryonic stem cells and cardiac cell fate.

Adipose-derived cardiomyogenic cells: in vitro expansion and functional improvement in a mouse model of myocardial infarction.

Interplay of Oct4 with Sox2 and Sox17: a molecular switch from stem cell pluripotency to specifying a cardiac fate.

Nano-scale control of cellular environment to drive embryonic stem cells selfrenewal and fate.

Human embryonic and induced pluripotent stem cells in basic and clinical research in cardiology.

A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates.

[The dual role of OCT4].

Calmodulin: a gatekeeper for ryanodine receptor function in the myocardium.

Cardiac regeneration: still a 21st century challenge in search for cardiac progenitors from stem cells and embryos.

Composite cell sheets: a further step toward safe and effective myocardial regeneration by cardiac progenitors derived from embryonic stem cells.

Immune response to human embryonic stem cell-derived cardiac progenitors and adipose-derived stromal cells.

TAp63 is important for cardiac differentiation of embryonic stem cells and heart development.

[Unexpected role for p63 during heart development: one phenotype can hide another one].

[Pluripotent stem cells: a cell model for early cardiac development].

Early cardiac development: a view from stem cells to embryos.

Embryological origin of the endocardium and derived valve progenitor cells: from developmental biology to stem cell-based valve repair.

Long-term functional benefits of epicardial patches as cell carriers.

Myoblasts and embryonic stem cells differentially engraft in a mouse model of genetic dilated cardiomyopathy.

Could a pluripotent stem cell give rise to a high yield of a single cell lineage: a myocardial cell?

Embryonic stem cell-derived cardiac myocytes are not ready for human trials.

MicroRNA-21 coordinates human multipotent cardiovascular progenitors therapeutic potential.

A view of bivalent epigenetic marks in two human embryonic stem cell lines reveals a different cardiogenic potential.

Response to letter regarding article, "Embryonic stem cell-derived cardiac myocytes are not ready for human trials".

Targeting cardiac fibroblasts: the pressure is on.

Right ventricular failure secondary to chronic overload in congenital heart diseases: benefits of cell therapy using human embryonic stem cell-derived cardiac progenitors.

A cohesin-OCT4 complex mediates Sox enhancers to prime an early embryonic lineage.

Msx1CreERT2 knock-In allele: A useful tool to target embryonic and adult cardiac valves.

Cardiac fibroblasts: from development to heart failure.

Mutations in DCHS1 cause mitral valve prolapse.

Concise Review: Pluripotent Stem Cell-Derived Cardiac Cells, A Promising Cell Source for Therapy of Heart Failure: Where Do We Stand?

Origins of cardiac fibroblasts.

Calreticulin secures calcium-dependent nuclear pore competency required for cardiogenesis.